One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study von Lewiecki, E Michael, Dinavahi, Rajani V, Lazaretti‐Castro, Marise, Ebeling, Peter R, Adachi, Jonathan D, Miyauchi, Akimitsu, Gielen, Evelien, Milmont, Cassandra E, Libanati, Cesar, Grauer, Andreas

Volltext

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension von Miyauchi, Akimitsu, Dinavahi, Rajani V., Crittenden, Daria B., Yang, Wenjing, Maddox, Judy C., Hamaya, Etsuro, Nakamura, Yoichi, Libanati, Cesar, Grauer, Andreas, Shimauchi, Junichiro

Volltext

Human immunodeficiency virus and renal transplantation von Dinavahi, Rajani V., Mehrotra, Anita, Murphy, Barbara T., Huprikar, Shirish

Volltext

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study von Lewiecki, E. Michael, Dinavahi, Rajani V, Lazaretti-Castro, Marise, Ebeling, Peter R, Adachi, Jonathan D, Miyauchi, Akimitsu, Gielen, Evelien, Milmont, Cassandra E, Libanati, Cesar, Grauer, Andreas

Volltext

Laparoscopic appearance of fasciola hepatica infection von Neff, Guy W., Dinavahi, Rajani V., Chase, VeEtta, Reddy, K.Rajender

Volltext